FealtySign in

CARDINAL HEALTH INC

(CAH)

CIK 721371 · SEC filings only

Not gradedDividend record
shown as history
company entity
53 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

53 declarations · 18 raised · 34 held · 0 cut · held 52 quarters

  1. HELD$0.5107/shperiod ended 2025-12-31Filing ↗
  2. RAISED$0.5107/shperiod ended 2025-09-30Filing ↗
  3. HELD$0.5056/shperiod ended 2025-03-31Filing ↗
  4. HELD$0.5056/shperiod ended 2024-12-31Filing ↗
  5. RAISED$0.5056/shperiod ended 2024-09-30Filing ↗
  6. HELD$0.5006/shperiod ended 2024-03-31Filing ↗
  7. HELD$0.5006/shperiod ended 2023-12-31Filing ↗
  8. RAISED$0.5006/shperiod ended 2023-09-30Filing ↗
  9. HELD$0.4957/shperiod ended 2023-03-31Filing ↗
  10. HELD$0.4957/shperiod ended 2022-12-31Filing ↗
  11. RAISED$0.4957/shperiod ended 2022-09-30Filing ↗
  12. HELD$0.4908/shperiod ended 2022-03-31Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
3 resolved promises

Not enough resolved promises to grade

3 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (3)

Open · buyback authorization

raising its share repurchase expectations in fiscal year 2025 by $250 million to a total of $750 million

next filing due$750.0000receipt →
Open · buyback authorization

Share repurchases ~$750 million

resolves in ~336 days$750.0000receipt →
Open · buyback authorization

Cardinal Health Board of Directors approved a $5.0 billion increase to the share repurchase program

resolves in ~701 days$5.0000receipt →

Credibility timeline

KEPT · Feb 1, 2024KEPT · Nov 1, 2024KEPT · Aug 11, 2026
20242026
Timeline as a list
  • Feb 1, 2024KEPTBoard of Directors approved a 3-year authorization to repurchase up to an additional $3 billion of Cardinal Health common shares
  • Nov 1, 2024KEPTShare repurchases $1.5B - $2.0B
  • Aug 11, 2026KEPTBaseline share repurchases $500M
3 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
Not yet gradedGuidance record
harness minimum not met
company entity
0 resolved promises

Not enough GAAP-comparable guidance to grade

0 of the 4 resolved guidance promises needed to publish a reliability grade. Much of this company’s guidance is non-GAAP, which has no comparable GAAP actual in SEC XBRL to check it against — shown below, never scored. Here's what we're tracking — we never show a grade we can't back with receipts.

Pro

guidance history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (38)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Aug 11, 2026
    Cardinal Health provides fiscal year 2027 non-GAAP EPS guidance 2 of 13% to 15% growth 3 ($12.40 to $12.60)
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Apr 30, 2026
    Cardinal Health is raising and narrowing its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.70 to $10.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 5, 2026
    Cardinal Health is raising its fiscal year 2026 guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $10.15 to $10.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Oct 30, 2025
    Cardinal Health is raising its guidance for non-GAAP diluted EPS attributable to Cardinal Health, Inc. to a range of $9.65 to $9.85
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Aug 12, 2025
    The company raised its fiscal year 2026 outlook for non-GAAP diluted EPS to $9.30 to $9.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · May 1, 2025
    raised and narrowed to $8.05 to $8.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · May 1, 2025
    Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Jan 30, 2025
    The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $7.85 to $8.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Nov 1, 2024
    The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $7.75 to $7.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Aug 14, 2024
    Fiscal year 2025 non-GAAP EPS guidance raised to $7.55 to $7.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · May 2, 2024
    raised and narrowed to $7.30 to $7.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · May 2, 2024
    at least $7.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Feb 1, 2024
    Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Nov 3, 2023
    The company raised its fiscal 2024 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $6.75 to $7.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Aug 15, 2023
    Fiscal year 2024 non-GAAP EPS guidance raised to $6.50 to $6.75
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · May 4, 2023
    Fiscal year 2023 non-GAAP EPS guidance raised and narrowed to $5.60 to $5.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Feb 2, 2023
    The company updated its fiscal year 2023 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.20 to $5.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Nov 4, 2022
    The company reaffirmed its fiscal year 2023 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. of $5.05 to $5.40.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Aug 11, 2022
    Non-GAAP earnings per share $5.05 - $5.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · May 5, 2022
    The company updated its fiscal year 2022 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.15 to $5.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Feb 3, 2022
    The company updated its fiscal year 2022 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.15 to $5.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Nov 9, 2021
    The company reaffirmed its fiscal year 2022 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. of $5.60 to $5.90.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Aug 5, 2021
    Non-GAAP earnings per share $5.60 - $5.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · May 6, 2021
    Cardinal Health narrowed its fiscal year 2021 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.90 to $6.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Feb 5, 2021
    Cardinal Health raised its fiscal year 2021 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.85 to $6.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Nov 5, 2020
    Cardinal Health is updating its fiscal year 2021 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $5.65 to $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · May 3, 2012
    revised range of $3.15 to $3.20 for fiscal 2012 non-GAAP diluted earnings per share from continuing operations
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance fy · Oct 27, 2011
    The company reaffirmed its fiscal 2012 outlook for non-GAAP diluted earnings per share of $3.04 to $3.19.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Apr 28, 2011
    we are increasing our full-year guidance for non-GAAP diluted EPS from continuing operations to $2.61 to $2.67
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Oct 28, 2010
    we have become more confident in achieving the higher end of our non-GAAP diluted EPS guidance range of $2.38 to $2.48
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Apr 29, 2010
    preliminary view of fiscal 2011 non-GAAP diluted EPS from continuing operations is in the range of $2.35 to $2.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance fy · Apr 29, 2010
    non-GAAP diluted EPS from continuing operations for fiscal 2010 will be in the range of $2.15 to $2.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Nov 5, 2009
    we expect that our full-year performance will likely be toward the higher end of our guidance of $1.90 to $2.00 for non-GAAP diluted EPS from continuing operations
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance fy · Apr 30, 2009
    we are maintaining our full-year non-GAAP EPS outlook within, but at the low end of, our guidance range of $3.50 to $3.60 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Jan 8, 2009
    we anticipate full-year non-GAAP EPS to be in a range of $3.50 to $3.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance q · Jan 8, 2009
    Non-GAAP diluted EPS from continuing operations 1 for the company’s fiscal second quarter, ended Dec. 31, 2008, is anticipated to be at least $0.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · Jul 8, 2008
    non-GAAP diluted earnings per share from continuing operations 1 for fiscal 2008 are expected to be about in the middle of a $3.75 to $3.85 range
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance fy · Jan 29, 2008
    Cardinal Health now expects non-GAAP EPS to be in a range of $3.75 to $3.85 for the year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
0 resolved guidance promises · 38dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →